{"id":"maz-101association","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Hyperthyroidism"},{"rate":"1-5%","effect":"Fatigue"},{"rate":"1-5%","effect":"Nausea"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Rash"},{"rate":"1-5%","effect":"Pruritus"},{"rate":"1-5%","effect":"Pyrexia"},{"rate":"1-5%","effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MAZ-101association works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 ligands on tumor cells, and thereby enhancing the immune response against cancer cells.","oneSentence":"MAZ-101association is a drug that targets the PD-1/PD-L1 pathway to modulate the immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:20.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05684380","phase":"PHASE3","title":"Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)","status":"UNKNOWN","sponsor":"EMS","startDate":"2024-09","conditions":"Allergic Rhinitis","enrollment":514}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MAZ-101association","genericName":"MAZ-101association","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MAZ-101association is a drug that targets the PD-1/PD-L1 pathway to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}